MX375282B - Pirrolo[2,3-c]piridinas como agentes de formacion de imagenes para ovillos neurofibrilares. - Google Patents
Pirrolo[2,3-c]piridinas como agentes de formacion de imagenes para ovillos neurofibrilares.Info
- Publication number
- MX375282B MX375282B MX2016016384A MX2016016384A MX375282B MX 375282 B MX375282 B MX 375282B MX 2016016384 A MX2016016384 A MX 2016016384A MX 2016016384 A MX2016016384 A MX 2016016384A MX 375282 B MX375282 B MX 375282B
- Authority
- MX
- Mexico
- Prior art keywords
- aggregates
- tau
- alzheimer
- imaging
- pyridines
- Prior art date
Links
- RQMWVVBHJMUJNZ-UHFFFAOYSA-N 4-chloropyridin-2-amine Chemical compound NC1=CC(Cl)=CC=N1 RQMWVVBHJMUJNZ-UHFFFAOYSA-N 0.000 title 1
- 239000012216 imaging agent Substances 0.000 title 1
- 238000003384 imaging method Methods 0.000 abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000004770 neurodegeneration Effects 0.000 abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 2
- 230000007170 pathology Effects 0.000 abstract 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 1
- 102000003802 alpha-Synuclein Human genes 0.000 abstract 1
- 108090000185 alpha-Synuclein Proteins 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000002600 positron emission tomography Methods 0.000 abstract 1
- 150000005255 pyrrolopyridines Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2014/079834 WO2015188368A1 (en) | 2014-06-13 | 2014-06-13 | Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles |
| PCT/US2015/034794 WO2015191506A2 (en) | 2014-06-13 | 2015-06-09 | Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016016384A MX2016016384A (es) | 2017-05-01 |
| MX375282B true MX375282B (es) | 2025-03-06 |
Family
ID=54832744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016016384A MX375282B (es) | 2014-06-13 | 2015-06-09 | Pirrolo[2,3-c]piridinas como agentes de formacion de imagenes para ovillos neurofibrilares. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9808542B2 (enExample) |
| EP (1) | EP3154970B1 (enExample) |
| JP (1) | JP6513107B2 (enExample) |
| KR (1) | KR102478430B1 (enExample) |
| CN (1) | CN106661018B (enExample) |
| AU (1) | AU2015274843B2 (enExample) |
| BR (1) | BR112016028345B1 (enExample) |
| CA (1) | CA2948528C (enExample) |
| DK (1) | DK3154970T3 (enExample) |
| ES (1) | ES2763095T3 (enExample) |
| HU (1) | HUE048395T2 (enExample) |
| MX (1) | MX375282B (enExample) |
| PL (1) | PL3154970T3 (enExample) |
| RU (1) | RU2695373C2 (enExample) |
| WO (2) | WO2015188368A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2894994C (en) | 2012-12-21 | 2019-11-12 | National Institute Of Radiological Sciences | Compounds for imaging tau proteins that accumulate in brain |
| EP3487545A1 (en) | 2016-07-22 | 2019-05-29 | AC Immune S.A. | Compounds for imaging tau protein aggregates |
| CN115650982A (zh) | 2016-07-22 | 2023-01-31 | Ac免疫有限公司 | 用于成像tau蛋白聚集体的化合物 |
| EP3636262A4 (en) | 2017-06-02 | 2020-06-10 | FUJIFILM Toyama Chemical Co., Ltd. | AGENT FOR PREVENTING OR TREATING ALZHEIMER-LIKE DEMENTIA |
| US11660287B2 (en) | 2017-06-02 | 2023-05-30 | Fujifilm Toyama Chemical Co., Ltd. | Agent for preventing or treating spinocerebellar ataxia |
| MX393052B (es) | 2017-06-02 | 2025-03-24 | Fujifilm Toyama Chemical Co Ltd | Agente para prevenir o tratar atrofia cerebral. |
| BR112019024983A2 (pt) | 2017-06-02 | 2020-06-23 | Fujifilm Toyama Chemical Co., Ltd. | Agente para reduzir a quantidade de proteína b amiloide |
| WO2018221731A1 (ja) * | 2017-06-02 | 2018-12-06 | 富山化学工業株式会社 | タウオパチー予防または治療剤 |
| EP3705121B1 (en) | 2017-10-30 | 2023-08-30 | FUJIFILM Toyama Chemical Co., Ltd. | Emopamil binding protein binding agent and use thereof |
| EP3743423A1 (en) | 2018-01-24 | 2020-12-02 | AC Immune SA | Gamma-carboline compounds for the detection of tau aggregates |
| EP3743426A1 (en) | 2018-01-24 | 2020-12-02 | AC Immune SA | Azacarboline compounds for the detection of tau aggregates |
| WO2019192533A1 (zh) * | 2018-04-04 | 2019-10-10 | 深圳福沃药业有限公司 | 用于治疗乳腺癌的雌激素受体降解剂 |
| KR102017324B1 (ko) * | 2018-04-30 | 2019-09-02 | 경북대학교 산학협력단 | 신규한 asm 활성 직접 억제 화합물 2-아미노-2-(1,2,3-트리아졸-4-일)프로판-1,3-디올 유도체 및 이의 용도 |
| JP7293343B2 (ja) * | 2018-05-09 | 2023-06-19 | アプリノイア セラピューティクス リミテッド | ヘテロアリール化合物及びその使用 |
| US12448374B2 (en) | 2018-06-07 | 2025-10-21 | Disarm Therapeutics, Inc. | Inhibitors of SARM1 |
| CN108676007B (zh) * | 2018-06-22 | 2020-06-26 | 厦门大学 | 放射性核素标记的苯并蝶啶类衍生物及其制备方法和应用 |
| EP3897670A4 (en) | 2018-12-19 | 2022-09-07 | Disarm Therapeutics, Inc. | MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS |
| KR20220100921A (ko) | 2019-11-13 | 2022-07-18 | 아프리노이아 테라퓨틱스 리미티드 | 타우 단백질 응집체를 분해하기 위한 화합물 및 이의 용도 |
| US20220008563A1 (en) * | 2020-07-10 | 2022-01-13 | The Regents Of The University Of California | Radiolabelled and nonradiolabelled pegylated compounds and uses thereof |
| WO2022031946A1 (en) * | 2020-08-06 | 2022-02-10 | Chdi Foundation, Inc. | Heterobiaryl compounds and imaging agents for imaging huntingtin protein |
| CN112939753B (zh) * | 2020-09-15 | 2022-04-05 | 浙江大学 | 一种1-茚酮类化合物的合成方法 |
| KR102240400B1 (ko) * | 2020-11-19 | 2021-04-15 | 한국원자력연구원 | 베타-아밀로이드 검출용 수용성 화합물 |
| CN112745299B (zh) * | 2021-01-07 | 2022-01-25 | 温州大学 | 4-氰基-7,8-二氢异喹啉衍生物及其制备方法和应用 |
| TWI782769B (zh) * | 2021-10-28 | 2022-11-01 | 行政院原子能委員會核能研究所 | 一種新穎神經纖維糾結微管相關蛋白質Tau造影化合物、其製備方法及用途 |
| CN114149425A (zh) * | 2021-11-16 | 2022-03-08 | 上海应用技术大学 | 5-氟甲基吡啶衍生物和18-f同位素标记的5-氟甲基吡啶衍生物及其制备与应用 |
| CN114276259B (zh) * | 2022-01-04 | 2022-12-06 | 济川(上海)医学科技有限公司 | 一种马来酸二甲茚定关键中间体的制备方法 |
| CN115417816B (zh) * | 2022-09-05 | 2024-01-26 | 江苏南大光电材料股份有限公司 | 一种3,6-二溴-1-氯-异喹啉的制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5451566A (en) * | 1993-11-17 | 1995-09-19 | Zeneca Limited | Herbicidal pyrrolopyridine compounds |
| JP5635727B2 (ja) * | 2004-10-07 | 2014-12-03 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | チアゾリルｍｇｌｕｒ５アンタゴニスト及びそれらの使用のための方法 |
| US20080027044A1 (en) | 2006-06-13 | 2008-01-31 | Kim Lewis | Prodrug antibiotic screens |
| WO2008103615A1 (en) | 2007-02-21 | 2008-08-28 | Kalypsys, Inc. | Isoquinolines useful as inducible nitric oxide synthase inhibitors |
| TW200902499A (en) | 2007-05-15 | 2009-01-16 | Astrazeneca Ab | New compounds |
| WO2009155024A1 (en) * | 2008-05-30 | 2009-12-23 | Merck & Co., Inc. | Novel substituted indoles |
| JP5789252B2 (ja) | 2009-05-07 | 2015-10-07 | インテリカイン， エルエルシー | 複素環式化合物およびその使用 |
| GB201004311D0 (en) * | 2010-03-15 | 2010-04-28 | Proximagen Ltd | New enzyme inhibitor compounds |
| CN103298474B (zh) | 2010-11-10 | 2016-06-29 | 无限药品股份有限公司 | 杂环化合物及其用途 |
| CA2825599C (en) | 2011-02-01 | 2021-07-13 | The Board Of Trustees Of The University Of Illinois | 4-methyl-n-hydroxybenzamide compounds as histone deacetylase (hdac) inhibitors |
| US8684313B2 (en) | 2011-02-02 | 2014-04-01 | Ocean Rodeo Sports Inc. | Inflatable kite with leading edge swept forwards at wingtip |
| WO2013040183A1 (en) * | 2011-09-16 | 2013-03-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Beta-amyloid imaging agents, methods of manufacture, and methods of use thereof |
| EP2855477A4 (en) * | 2012-05-29 | 2015-11-18 | Merck Sharp & Dohme | ISOTOPICALLY MARKED BIARYL UREA COMPOUNDS |
| CN103450152B (zh) * | 2012-06-04 | 2015-11-18 | 济南海乐医药技术开发有限公司 | 基于吲唑、吲哚或氮杂吲唑、氮杂吲哚的双芳基脲类结构抗肿瘤药物 |
| GB201304526D0 (en) | 2013-03-13 | 2013-04-24 | Proximagen Ltd | New compounds |
| GB201404498D0 (en) * | 2014-03-13 | 2014-04-30 | Proximagen Ltd | New compounds |
-
2014
- 2014-06-13 WO PCT/CN2014/079834 patent/WO2015188368A1/en not_active Ceased
-
2015
- 2015-06-09 ES ES15806980T patent/ES2763095T3/es active Active
- 2015-06-09 BR BR112016028345-7A patent/BR112016028345B1/pt active IP Right Grant
- 2015-06-09 DK DK15806980.7T patent/DK3154970T3/da active
- 2015-06-09 MX MX2016016384A patent/MX375282B/es active IP Right Grant
- 2015-06-09 AU AU2015274843A patent/AU2015274843B2/en active Active
- 2015-06-09 PL PL15806980T patent/PL3154970T3/pl unknown
- 2015-06-09 JP JP2016572520A patent/JP6513107B2/ja active Active
- 2015-06-09 RU RU2016150404A patent/RU2695373C2/ru active
- 2015-06-09 CN CN201580031335.2A patent/CN106661018B/zh active Active
- 2015-06-09 HU HUE15806980A patent/HUE048395T2/hu unknown
- 2015-06-09 US US15/317,333 patent/US9808542B2/en active Active
- 2015-06-09 KR KR1020177000709A patent/KR102478430B1/ko active Active
- 2015-06-09 WO PCT/US2015/034794 patent/WO2015191506A2/en not_active Ceased
- 2015-06-09 CA CA2948528A patent/CA2948528C/en active Active
- 2015-06-09 EP EP15806980.7A patent/EP3154970B1/en active Active
-
2017
- 2017-10-04 US US15/724,402 patent/US10022461B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015274843A1 (en) | 2016-11-10 |
| JP2017521387A (ja) | 2017-08-03 |
| CN106661018A (zh) | 2017-05-10 |
| BR112016028345B1 (pt) | 2022-11-29 |
| ES2763095T3 (es) | 2020-05-27 |
| EP3154970A4 (en) | 2017-11-15 |
| AU2015274843B2 (en) | 2018-11-22 |
| RU2019115483A (ru) | 2019-06-13 |
| DK3154970T3 (da) | 2020-01-20 |
| RU2695373C2 (ru) | 2019-07-23 |
| CN106661018B (zh) | 2019-07-19 |
| EP3154970B1 (en) | 2019-11-06 |
| BR112016028345A8 (pt) | 2021-06-29 |
| US9808542B2 (en) | 2017-11-07 |
| CA2948528A1 (en) | 2015-12-17 |
| MX2016016384A (es) | 2017-05-01 |
| WO2015191506A3 (en) | 2016-02-04 |
| US20170119912A1 (en) | 2017-05-04 |
| HUE048395T2 (hu) | 2020-08-28 |
| KR102478430B1 (ko) | 2022-12-15 |
| US20180071412A1 (en) | 2018-03-15 |
| WO2015191506A2 (en) | 2015-12-17 |
| RU2016150404A (ru) | 2018-07-18 |
| EP3154970A2 (en) | 2017-04-19 |
| RU2016150404A3 (enExample) | 2018-11-30 |
| PL3154970T3 (pl) | 2020-04-30 |
| WO2015188368A1 (en) | 2015-12-17 |
| CA2948528C (en) | 2022-05-31 |
| KR20170016481A (ko) | 2017-02-13 |
| US10022461B2 (en) | 2018-07-17 |
| BR112016028345A2 (pt) | 2017-08-22 |
| JP6513107B2 (ja) | 2019-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX375282B (es) | Pirrolo[2,3-c]piridinas como agentes de formacion de imagenes para ovillos neurofibrilares. | |
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| ECSP088645A (es) | Nuevos benzotiazoles sustituidos con heteroaril | |
| MX375424B (es) | Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-il carbamato y derivados de 1,1,1-trifluoro-4- hidroxibutan-2-il carbamato como inhibidores de magl | |
| EA201890852A1 (ru) | Соли валбеназина и их полиморфы | |
| CY1120334T1 (el) | Υποκατεστημενης 3-αλλογονοαλυλαμινης αναστολεις ssao και χρησεις αυτων | |
| CL2020001097A1 (es) | Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6. | |
| UA113186C2 (xx) | Макроциклічні інгібітори lrrk2 кінази | |
| EA201400392A1 (ru) | ПРОИЗВОДНЫЕ 6-ЗАМЕЩЕННЫХ ТРИАЗОЛОПИРИДАЗИНОВ КАК АГОНИСТЫ Rev-Erb | |
| BR112015025140A2 (pt) | 2-fenilimidazo[1,2-a]pirimidinas como agentes de imagem | |
| EA201390772A1 (ru) | Новые соли и полиморфные формы афатиниба | |
| MX377305B (es) | DERIVADOS DE IMIDAZO[4,5-c]QUINOLINA E IMIDAZO[4,5-c][1,5]NAFTIRIDINA NOVEDOSOS COMO INHIBIDORES DE LRRK2. | |
| UA116774C2 (uk) | Інгібітори серин/треонінкінази | |
| MX2009007487A (es) | Derivados de imidazo[1,2-a]piridina substituidos de heteroarilo novedosos. | |
| EA201391263A1 (ru) | Комбинированные терапии гематологических опухолей | |
| MX385045B (es) | Anticuerpo monoclonal recombinante para usarse en el tratamiento de la enfermedad de alzheimer. | |
| UA114944C2 (uk) | Піридинільні і конденсовані піридинільні похідні триазолону | |
| AR095371A1 (es) | Derivados de 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftalmológicos | |
| BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
| EP2811832A4 (en) | USE OF LAQUINIMOD FOR THE TREATMENT OF PATIENTS WITH MORBUS CROHN AFTER FAILED PREVIOUS ANTI-TNF THERAPY | |
| PE20160159A1 (es) | Derivados de diazacarbazol como ligandos de tau para pet | |
| EA032951B1 (ru) | Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения | |
| CO6341628A2 (es) | \\\\\\\"nuevos compuestos adecuados como precursores de compuestos que son utiles para obtener imegenes de depositos amiloides\\\\\\\" | |
| EA201691058A1 (ru) | Производные пирролопирролона и их применение для лечения заболеваний | |
| EA201591021A1 (ru) | 4-гидрокси-2-метил-5-(пропан-2-илиден)циклогекс-3-энекарбальдегид в профилактике и лечении когнитивных, нейродегенеративных или нейронных заболеваний |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |